TARACTAN
LOE ApproachingNDAORALTABLET
Approved
May 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARACTAN is an oral small-molecule tablet approved in 1962 by Roche for an unknown indication. The mechanism of action and pharmacologic class are not publicly documented in available data.
LOE Approaching
As an aging oral small molecule approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely in defensive/optimization mode with reduced headcount expectations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for TARACTAN roles. Working on this legacy product offers stability but limited growth; career advancement typically requires transition to newer, higher-priority assets within the Roche portfolio.
Brand ManagerField Sales Representative
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.